Mediantechnologies (ALMDT) Company Profile (Euronext EU): FKnol.com

Stock Screener for Euronext EU Stocks (Sector-wise)

Mediantechnologies, whose shares are listed on and trade on the Euronext EU stock exchange, has the following business profile:

Company's Full Name:	Median Technologies SA
Short Name:	Mediantechnologies
Trading Ticker Symbol:	ALMDT
Primary Exchange(s):	Euronext Growth Paris
Exchange Code:	PAR
ISIN:	FR0011049824
Headquarter/Listing Location:	Valbonne, France
Primary Industry Sector:	Healthcare
Secondary Sub-sector:	Members Only! Login / Register to view
Main Business Areas/Categories:	Members Only! Login / Register to view

Market and Trading Information for Mediantechnologies (Euronext EU)

The following details are available for trading and market data about the stock of Mediantechnologies as of writing. Currency is EUR.

Current Share Price:	EUR 4.75
Previous Year's Closing Price:	EUR 8.89
Percentage Price Change (YTD):	-46.57%
Market Cap:	91.86 million
52-week Price Range:	3.74 - 8.92
Dividend Per Share:	0
EPS (TTM):	-1.35
Price-Earnings (Trailing):	0
Price-Earnings (Forward):	-3.99
Currency:	EUR

Company Profile and Business Description for Mediantechnologies

Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiopsy (Imaging BIOmarker Phenotyping System), a phenomics imaging platform empower translational research with AI powered Biomarker identification tools and inform clinical decisions using CT scan similarity search for patient profiling services; and iSee for image analysis and management in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California San Diego to conduct a study for its proprietary imaging platform iBiopsy validation. The company was founded in 2002 and is based in Valbonne, France.